Cefaly develops non-invasive neuromodulation devices for migraine treatment and prevention. The company operates in the regulated medical-device layer rather than the general wellness market, with products built around external trigeminal nerve stimulation delivered through a wearable device positioned on the forehead. Its current positioning centers on drug-free, at-home migraine care for adult users.

The system delivers controlled electrical stimulation through the skin to the upper branch of the trigeminal nerve, a pathway closely tied to migraine generation and pain processing. Current Cefaly devices support both acute treatment during attacks and repeated preventive sessions, combining a relatively simple wearable form factor with repeatable neuromodulation protocols for home use. The platform is best understood as a consumer-accessible but clinically regulated neurostimulation system rather than a general-purpose consumer wearable.

Cefaly targets adults with migraine who want non-pharmacological options for symptom relief and attack reduction. The device is designed for self-administered use outside the clinic, placing it within the broader group of home-use neuromodulation products for chronic neurological conditions. Within the neurotech ecosystem, Cefaly is a relatively established example of external nerve stimulation translated into a direct-to-patient migraine device.